ProPhase Historical Income Statement

PRPH Stock

USD 0.26 0.02 8.33%

Historical analysis of ProPhase Labs income statement accounts such as Other Operating Expenses of 79.7 M, Total Operating Expenses of 45.7 M, Depreciation And Amortization of 8.1 M or Cost Of Revenue of 16.8 M can show how well ProPhase Labs performed in making a profits. Evaluating ProPhase Labs income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ProPhase Labs's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining ProPhase Labs latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ProPhase Labs is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.

About ProPhase Income Statement Analysis

ProPhase Labs Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ProPhase Labs shareholders. The income statement also shows ProPhase investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

ProPhase Labs Income Statement Chart

As of now, ProPhase Labs' Depreciation And Amortization is increasing as compared to previous years. The ProPhase Labs' current Research Development is estimated to increase to about 1.4 M, while Selling General Administrative is projected to decrease to under 29.5 M.

Selling General Administrative Total Revenue Gross Profit Other Operating Expenses

Total Revenue

Total revenue comprises all receipts ProPhase Labs generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of ProPhase Labs minus its cost of goods sold. It is profit before ProPhase Labs operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ProPhase Labs. It is also known as ProPhase Labs overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from ProPhase Labs' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ProPhase Labs current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.As of now, ProPhase Labs' Depreciation And Amortization is increasing as compared to previous years. The ProPhase Labs' current Research Development is estimated to increase to about 1.4 M, while Selling General Administrative is projected to decrease to under 29.5 M.

	2022	2023	2024	2025 (projected)
Gross Profit	70.7M	16.2M	14.6M	14.0M
Total Revenue	122.6M	44.4M	51.0M	35.5M

Gross Profit Total Revenue

ProPhase Labs income statement Correlations

	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Net Income	Income Tax Expense	Depreciation And Amortization	Cost Of Revenue	Income Before Tax	Total Other Income Expense Net	Research Development	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Operating Income Net Other	Discontinued Operations	Non Recurring	Interest Income	Extraordinary Items	Net Interest Income	Reconciled Depreciation
Interest Expense		0.84	0.6	0.38	0.88	-0.34	-0.38	-0.15	0.85	-0.38	-0.23	0.98	0.68	-0.43	-0.47	0.34	-0.19	-0.19	0.18	-0.12	-0.67	0.34	-0.13	-0.87	0.97
Selling General Administrative	0.84		0.86	0.75	0.97	0.01	0.0	0.23	0.94	-0.16	-0.02	0.9	0.83	-0.18	-0.39	0.26	-0.24	0.19	0.13	-0.14	-0.42	0.25	-0.14	-0.84	0.92
Total Revenue	0.6	0.86		0.96	0.88	0.47	0.45	0.64	0.75	0.11	0.21	0.64	0.9	0.13	-0.48	-0.03	-0.27	0.6	0.01	-0.16	-0.11	0.46	-0.16	-0.64	0.66
Gross Profit	0.38	0.75	0.96		0.76	0.62	0.61	0.77	0.65	0.2	0.35	0.44	0.79	0.28	-0.36	-0.04	-0.23	0.73	-0.12	-0.19	0.02	0.31	-0.2	-0.51	0.48
Other Operating Expenses	0.88	0.97	0.88	0.76		0.03	0.0	0.24	0.96	-0.19	0.0	0.91	0.81	-0.23	-0.49	0.25	-0.32	0.19	0.07	-0.17	-0.51	0.33	-0.18	-0.85	0.92
Operating Income	-0.34	0.01	0.47	0.62	0.03		0.99	0.97	-0.16	0.62	0.44	-0.32	0.36	0.78	-0.01	-0.56	0.07	0.97	-0.07	-0.02	0.52	0.37	-0.01	0.26	-0.3
Ebit	-0.38	0.0	0.45	0.61	0.0	0.99		0.97	-0.18	0.61	0.47	-0.36	0.32	0.78	-0.01	-0.56	0.07	0.96	-0.08	-0.02	0.53	0.3	-0.01	0.28	-0.33
Ebitda	-0.15	0.23	0.64	0.77	0.24	0.97	0.97		0.04	0.56	0.45	-0.12	0.53	0.72	-0.13	-0.5	0.02	0.98	-0.03	-0.05	0.41	0.4	-0.05	0.07	-0.09
Total Operating Expenses	0.85	0.94	0.75	0.65	0.96	-0.16	-0.18	0.04		-0.34	-0.01	0.91	0.66	-0.36	-0.38	0.46	-0.32	0.0	-0.03	-0.21	-0.61	0.07	-0.22	-0.89	0.93
Net Income	-0.38	-0.16	0.11	0.2	-0.19	0.62	0.61	0.56	-0.34		-0.38	-0.37	0.06	0.47	0.13	-0.61	0.0	0.62	0.3	0.77	0.45	0.37	0.77	0.5	-0.36
Income Tax Expense	-0.23	-0.02	0.21	0.35	0.0	0.44	0.47	0.45	-0.01	-0.38		-0.21	0.12	0.41	-0.11	0.04	0.13	0.37	-0.49	-0.85	0.25	-0.19	-0.85	-0.05	-0.18
Depreciation And Amortization	0.98	0.9	0.64	0.44	0.91	-0.32	-0.36	-0.12	0.91	-0.37	-0.21		0.69	-0.41	-0.42	0.38	-0.19	-0.16	0.2	-0.12	-0.69	0.28	-0.13	-0.88	0.99
Cost Of Revenue	0.68	0.83	0.9	0.79	0.81	0.36	0.32	0.53	0.66	0.06	0.12	0.69		0.25	-0.46	0.01	0.07	0.48	0.09	-0.14	-0.11	0.56	-0.15	-0.68	0.7
Income Before Tax	-0.43	-0.18	0.13	0.28	-0.23	0.78	0.78	0.72	-0.36	0.47	0.41	-0.41	0.25		0.27	-0.3	0.68	0.7	-0.14	-0.06	0.46	0.11	-0.06	0.28	-0.37
Total Other Income Expense Net	-0.47	-0.39	-0.48	-0.36	-0.49	-0.01	-0.01	-0.13	-0.38	0.13	-0.11	-0.42	-0.46	0.27		-0.05	0.35	-0.02	0.05	0.11	0.11	-0.6	0.12	0.39	-0.37
Research Development	0.34	0.26	-0.03	-0.04	0.25	-0.56	-0.56	-0.5	0.46	-0.61	0.04	0.38	0.01	-0.3	-0.05		0.19	-0.54	-0.52	-0.35	-0.44	-0.47	-0.35	-0.61	0.39
Selling And Marketing Expenses	-0.19	-0.24	-0.27	-0.23	-0.32	0.07	0.07	0.02	-0.32	0.0	0.13	-0.19	0.07	0.68	0.35	0.19		-0.01	-0.15	-0.09	0.09	-0.15	-0.09	0.07	-0.17
Net Income From Continuing Ops	-0.19	0.19	0.6	0.73	0.19	0.97	0.96	0.98	0.0	0.62	0.37	-0.16	0.48	0.7	-0.02	-0.54	-0.01		0.0	0.01	0.47	0.4	0.01	0.12	-0.13
Non Operating Income Net Other	0.18	0.13	0.01	-0.12	0.07	-0.07	-0.08	-0.03	-0.03	0.3	-0.49	0.2	0.09	-0.14	0.05	-0.52	-0.15	0.0		0.48	-0.15	0.43	0.48	0.25	0.19
Discontinued Operations	-0.12	-0.14	-0.16	-0.19	-0.17	-0.02	-0.02	-0.05	-0.21	0.77	-0.85	-0.12	-0.14	-0.06	0.11	-0.35	-0.09	0.01	0.48		0.07	0.24	1.0	0.37	-0.13
Non Recurring	-0.67	-0.42	-0.11	0.02	-0.51	0.52	0.53	0.41	-0.61	0.45	0.25	-0.69	-0.11	0.46	0.11	-0.44	0.09	0.47	-0.15	0.07		0.07	0.07	0.51	-0.69
Interest Income	0.34	0.25	0.46	0.31	0.33	0.37	0.3	0.4	0.07	0.37	-0.19	0.28	0.56	0.11	-0.6	-0.47	-0.15	0.4	0.43	0.24	0.07		0.23	-0.05	0.22
Extraordinary Items	-0.13	-0.14	-0.16	-0.2	-0.18	-0.01	-0.01	-0.05	-0.22	0.77	-0.85	-0.13	-0.15	-0.06	0.12	-0.35	-0.09	0.01	0.48	1.0	0.07	0.23		0.38	-0.14
Net Interest Income	-0.87	-0.84	-0.64	-0.51	-0.85	0.26	0.28	0.07	-0.89	0.5	-0.05	-0.88	-0.68	0.28	0.39	-0.61	0.07	0.12	0.25	0.37	0.51	-0.05	0.38		-0.88
Reconciled Depreciation	0.97	0.92	0.66	0.48	0.92	-0.3	-0.33	-0.09	0.93	-0.36	-0.18	0.99	0.7	-0.37	-0.37	0.39	-0.17	-0.13	0.19	-0.13	-0.69	0.22	-0.14	-0.88

Click cells to compare fundamentals

ProPhase Labs Account Relationship Matchups

ProPhase Labs income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Interest Expense	295K	1.1M	764K	1.3M	1.5M	1.5M
Selling General Administrative	6.7M	22.5M	46.4M	34.5M	31.1M	29.5M
Total Revenue	14.5M	79.0M	122.6M	44.4M	51.0M	35.5M
Gross Profit	4.6M	32.8M	70.7M	16.2M	14.6M	14.0M
Other Operating Expenses	18.5M	69.2M	99.1M	66.0M	75.9M	79.7M
Operating Income	(4.0M)	9.8M	23.6M	(21.6M)	(19.5M)	(18.5M)
Ebit	(2.0M)	6.5M	23.7M	(21.5M)	(19.4M)	(18.4M)
Ebitda	(1.5M)	11.4M	28.7M	(14.8M)	(13.3M)	(12.7M)
Total Operating Expenses	8.6M	23.0M	47.1M	37.9M	43.5M	45.7M
Net Income	(2.4M)	6.3M	18.5M	(16.8M)	(19.3M)	(18.3M)
Income Tax Expense	94K	(968K)	4.4M	(6.0M)	(5.4M)	(5.1M)
Depreciation And Amortization	531K	4.9M	5.1M	6.7M	7.7M	8.1M
Cost Of Revenue	9.9M	46.2M	52.0M	28.1M	32.4M	16.8M
Income Before Tax	(2.3M)	5.3M	22.9M	(22.8M)	(20.5M)	(19.5M)
Total Other Income Expense Net	(221K)	(4.5M)	(687K)	(1.2M)	(1.1M)	(1.0M)
Research Development	633K	520K	652K	1.4M	1.3M	1.4M
Net Income Applicable To Common Shares	(1.7M)	(3.1M)	(2.1M)	6.3M	7.2M	7.6M
Selling And Marketing Expenses	1.1M	1.0M	1.3M	1.9M	1.7M	1.7M
Net Income From Continuing Ops	(2.3M)	6.3M	18.5M	(10.5M)	(12.0M)	(11.4M)
Interest Income	62K	642K	153K	69K	79.4K	75.4K
Tax Provision	12K	(968K)	4.4M	(5.8M)	(6.7M)	(6.4M)
Net Interest Income	(233K)	(506K)	(611K)	(841K)	(756.9K)	(719.1K)
Reconciled Depreciation	458K	3.6M	5.1M	5.8M	6.6M	7.0M

Currently Active Assets on Macroaxis

EBR	Centrais Electricas Brasileiras
HE	Hawaiian Electric Industries
VFC	VF Corporation
BVHMF	Vistry Group PLC
S	SentinelOne

When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:

How To Invest In ProPhase

Details

Is ProPhase Stock a good investment?

Details

What is ProPhase Labs' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.

You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.95)

Earnings Share

(1.53)

Revenue Per Share

0.996

Quarterly Revenue Growth

(0.81)

Return On Assets

(0.23)

The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ProPhase Historical Income Statement

About ProPhase Income Statement Analysis

ProPhase Labs Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

ProPhase Labs income statement Correlations

ProPhase Labs Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ProPhase Labs income statement Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Extraordinary Items	+ 1.0	Discontinued Operations
Ebit	+ 0.99	Operating Income
Reconciled Depreciation	+ 0.99	Depreciation And Amortization
Depreciation And Amortization	+ 0.98	Interest Expense
Net Income From Continuing Ops	+ 0.98	Ebitda
Reconciled Depreciation	+ 0.97	Interest Expense

Net Interest Income	- 0.89	Total Operating Expenses
Reconciled Depreciation	- 0.88	Net Interest Income
Net Interest Income	- 0.88	Depreciation And Amortization
Net Interest Income	- 0.87	Interest Expense
Extraordinary Items	- 0.85	Income Tax Expense
Discontinued Operations	- 0.85	Income Tax Expense